TetraPhase Pharmaceuticals Completes Enrollment Of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections
7/28/2014 8:44:45 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in IGNITE 1, its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAI). The Company expects to report top-line results from IGNITE 1 in early first quarter 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by